Lung Cancer

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Non-Small Cell Lung Cancer (Morpheus-Lung)
  • Disease/Condition: Lung
  • Principal Investigator: Sarah Goldberg
A Phase I/Ib Study of APX005M in Combination With Nivolumab and Cabiralizumab in Patients With Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma Whose Disease Has Progressed on Anti-PD- 1/PD-L1 Therapy
  • Disease/Condition: Lung | Melanoma, skin | Other Skin | Other Urinary
  • Principal Investigator: Harriet Kluger
A Phase 2 Study of Poziotinib in Patients With Non-Small Cell Lung Cancer, Locally Advanced or Metastatic, With EGFR or HER2 Exon 20 Insertion Mutation (POZITIVE20-1)
  • Disease/Condition: Lung
  • Principal Investigator: Sarah Goldberg
A Phase 1 Trial of MLN0128 (TAK-228) in Combination With Osimertinib (AZD9291) in Advanced EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC) After Progression on a Previous EGFR Tyrosine Kinase Inhibitor
  • Disease/Condition: Lung
  • Principal Investigator: Sarah Goldberg
Moving PD-1 Blockade With Pembrolizumab Into Concurrent Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer
  • Disease/Condition: Lung
  • Principal Investigator: Roy H. Decker
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
  • Disease/Condition: Anus | Bladder | Colon | Esophagus | Kidney | Lip, Oral Cavity and Pharynx | Lung | Other Digestive Organ | Other Endocrine System | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs | Other Urinary | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Stomach | Thyroid | Unknown Sites | Breast
  • Principal Investigator: Hari Deshpande
An Open-Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech− and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study
  • Disease/Condition: Lung
  • Principal Investigator: Scott Gettinger
A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination With Nivolumab in Subjects With Non-small Cell Lung Cancer and Subjects With Metastatic Melanoma
  • Disease/Condition: Lung | Melanoma, skin
  • Principal Investigator: Sarah Weiss
An Open-Label, Phase 1, First-In-Human Study of Safety and Tolerability of TRAIL Receptor Agonist ABBV-621 in Subjects With Previously Treated Solid Tumors and Hematologic Malignancies
  • Disease/Condition: Anus | Bladder | Breast - Female | Breast - Male | Colon | Esophagus | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Myeloid and Monocytic Leukemia | Non-Hodgkin's Lymphoma | Pancreas | Prostate | Rectum | Small Intestine | Stomach | Thyroid | Phase I
  • Principal Investigator: Patricia LoRusso
A phase II study of combination immunotherapy with ipilimumab and nivolumab in patients with advanced non-small cell lung cancer resistant to anti-PD-1-axis therapy
  • Disease/Condition: Lung
  • Principal Investigator: Scott Gettinger